Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5365
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease ; day:18 ; month:10 ; year:2018 ; pages:1-3
Bone marrow transplantation ; (18.10.2018), 1-3
- Urheber
-
Kaloyannidis, Panayotis
- Beteiligte Personen und Organisationen
-
Shaibani, Eshrak Al
Apostolidis, Ioannis
Kanfar, Solaf
Anezi, Khalid Al
Hashmi, Hani Al
SpringerLink (Online service)
- DOI
-
10.1038/s41409-018-0362-7
- URN
-
urn:nbn:de:101:1-2018112721570123606796
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kaloyannidis, Panayotis
- Shaibani, Eshrak Al
- Apostolidis, Ioannis
- Kanfar, Solaf
- Anezi, Khalid Al
- Hashmi, Hani Al
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Murine Models of Steroid Refractory Graft-versus-Host Disease
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Murine Models of Steroid Refractory Graft-versus-Host Disease
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Murine Models of Steroid Refractory Graft-versus-Host Disease
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial